Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorUniversity of Leeds
About this trial
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The primary aim is to find genetic determinants of GCA and PMR susceptibility, in order to yield novel insights into disease pathogenesis. A subset of the retrospective cohort is also enrolled in a post-marketing surveillance registry of patients eligible for, or receiving tocilizumab, to treat their relapsing or refractory GCA.
Eligibility criteria
Qualifiers
Willing to self-identify an ethnic group, such as Caucasian, Asian, Afro-Caribbean.
Have a firm clinical diagnosis of GCA or PMR, or (for patients identified prospectively) GCA or PMR should be more likely than any alternative explanation for the patient's symptoms.
Able and willing to give informed consent. Patients will be 50 years of age or over, unless both biopsy-proven and a clinically classical case of GCA.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
4,500 Participants
are grouped into 2 trial groupsLocations
76Queen Elizabeth The Queen Mother HospitalCT 1 3NG, CanterburyKent, United Kingdom
Whiston HospitalL35 5DR, PrescotMerseyside, United Kingdom
Nevill Hall Hospital, Aneurin Bevan University Health Board Abergavenny United Kingdom
Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust Aylesbury United Kingdom
Sponsors and collaborators
University of Leeds
Lead sponsor
University of Oxford
Collaborator
Source ClinicalTrials.gov